IMPACT BIOMEDICAL INC.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
IBO$4.62+6.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Balance Sheets as of September 30, 2026 (Unaudited) and December 31, 2025
| September 30, 2026(unaudited) | December 31, 2025 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash | $21,000 | $3,000 |
| Accounts receivable | - | 5,000 |
| Inventory | 56,000 | 63,000 |
| Current portion of notes receivable | 14,000 | 198,000 |
| Prepaid expenses and other current assets | 11,000 | 142,000 |
| Total current assets | 102,000 | 411,000 |
| Notes receivable | 185,000 | - |
| Other intangible assets, net | 16,140,000 | 16,994,000 |
| Total assets | $16,427,000 | $17,405,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $450,000 | $347,000 |
| Accrued expenses | 300,000 | 194,000 |
| Due to related party | 1,623,000 | 621,000 |
| Total current liabilities | 2,373,000 | 1,162,000 |
| Deferred tax liability, net | 688,000 | 688,000 |
| Total liabilities | 3,061,000 | 1,850,000 |
| Commitments and contingencies (Note 9) | - | |
| Stockholders’ equity | ||
| Preferred stock, $0.001 par value; 100,000,000 shares authorized, zero shares issued and outstanding (zero on December 31, 2025); Liquidation value $0.001 per share, zero aggregate. zero on December 31, 2025). | - | - |
| Common stock, $0.001 par value; 4,000,000,000 shares authorized, 8,544,066 shares issued and outstanding (8,290,489 on December 31, 2025) | 108,000 | 105,000 |
| Additional paid-in capital | 63,150,000 | 61,713,000 |
| Accumulated deficit | (53,139,000) | (49,507,000) |
| Total stockholders’ equity of the Company | 10,119,000 | 12,311,000 |
| Non-controlling interest in subsidiaries | 3,247,000 | 3,244,000 |
| Total stockholders’ equity | 13,366,000 | 15,555,000 |
| Total liabilities and stockholders’ equity | $16,427,000 | $17,405,000 |
Condensed Consolidated Statements of Operations
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue: | ||||
| Biotech retail sales | $21,000 | $18,000 | $31,000 | $25,000 |
| Total revenue | 21,000 | 18,000 | 31,000 | 25,000 |
| Costs and expenses: | ||||
| Cost of revenue | 6,000 | 1,000 | 8,000 | 2,000 |
| Sales, general and administrative compensation (inclusive of stock-based compensation) | 156,000 | 261,000 | 1,942,000 | 755,000 |
| Sales and marketing | - | 2,000 | 1,000 | 22,000 |
| Professional Fees | 96,000 | 234,000 | 446,000 | 868,000 |
| Research and development | 35,000 | 52,000 | 158,000 | 230,000 |
| Depreciation and Amortization | 284,000 | 288,000 | 853,000 | 859,000 |
| Rent and utilities | 19,000 | 19,000 | 55,000 | 56,000 |
| Other operating expenses | 73,000 | 109,000 | 207,000 | 345,000 |
| Total costs and expenses | 669,000 | 966,000 | 3,670,000 | 3,137,000 |
| Operating loss | (648,000) | (948,000) | (3,639,000) | (3,112,000) |
| Other income (expense): | ||||
| Interest income | 4,000 | 3,000 | 10,000 | 10,000 |
| Change in fair value of note payable, related party | - | (268,000) | - | (13,210,000) |
| Interest expense | - | (262,000) | - | (793,000) |
| Loss from operations before income taxes | (644,000) | (1,475,000) | (3,629,000) | (17,105,000) |
| Income tax benefit | - | - | - | - |
| Net loss | $(644,000) | $(1,475,000) | $(3,629,000) | $(17,105,000) |
| Income (loss) from operations attributed to noncontrolling interest | (1,000) | 5,000 | (3,000) | 22,000 |
| Net loss attributable to common stockholders | $(645,000) | $(1,470,000) | $(3,632,000) | $(17,083,000) |
| Loss per common share: | ||||
| Basic | $(0.08) | $(1.52) | $(0.43) | $(17.96) |
| Diluted | $(0.08) | $(1.52) | $(0.43) | $(17.96) |
| Shares used in computing loss per common share: | ||||
| Basic | 8,544,066 | 965,607 | 8,543,137 | 951,292 |
| Diluted | 8,544,066 | 965,607 | 8,543,137 | 951,292 |
Condensed Consolidated Statements of Stockholder’s Equity
| Common Stock · Preferred Stock · Additional Paid-in · Accumulated · Total Impact · Non- controlling Interest in | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Capital · Deficit · Equity · Subsidiary · Total | ||||||||||
| Balance, December 31, 2024 | 911,607 | $11,000 | 60,496,041 | $60,000 | $41,559,000 | $(37,669,000) | $3,961,000 | 3,276,000 | $7,237,000 | |
| Acquisition of DSS PureAir, Inc. assets | 43,189 | 1,000 | - | - | 819,000 | - | 820,000 | - | 820,000 | |
| Stock based payments for professional services rendered | 10,811 | - | - | - | 190,000 | - | 190,000 | - | 190,000 | |
| Stock based payments | - | - | - | - | 5,000 | - | 5,000 | - | 5,000 | |
| Net loss | - | - | - | - | - | (17,083,000) | (17,083,000) | (22,000) | (17,105,000) | |
| Balance, September 30, 2025 | 965,607 | $12,000 | 60,496,041 | $60,000 | $42,573,000 | $(54,752,000) | $(12,107,000) | $3,254,000 | $(8,853,000) | |
| Balance, December 31, 2025 | 8,290,489 | $105,000 | - | $ | - | $61,713,000 | $(49,507,000) | $12,311,000 | $3,244,000 | $15,555,000 |
| Stock based compensation | 253,577 | 3,000 | 1,437,000 | 1,440,000 | - | 1,440,000 | ||||
| Net income (loss) | - | - | - | - | - | (3,632,000) | (3,632,000) | 3,000 | (3,629,000) | |
| Balance, September 30, 2026 | 8,544,066 | $108,000 | - | $ | - | $63,150,000 | $(53,139,000) | $10,119,000 | $3,247,000 | $13,366,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.